Skip to main content
Premium Trial:

Request an Annual Quote

Helomics, ChemImage Partner on Prostate Cancer Monitoring Tech Development

NEW YORK — Predictive Oncology, formerly Precision Therapeutics, said today that its Helomics subsidiary has partnered with molecular imaging firm ChemImage to develop technology for monitoring how prostate cancer responds to treatment.

Under the terms of the agreement, ChemImage will provide Helomics with a set of human prostate biopsy and prostatectomy tissue samples for sequencing. Helomics will integrate the sequencing results and existing Raman spectroscopy data on the samples into its D-CHIP — or Dynamic Clinical Health Insights — artificial intelligence (AI) knowledgebase with the goal of building a predictive model of prostate cancer drug response.

Additional terms of the deal between the Pittsburgh-based companies was not disclosed.

"We believe that alliances of this kind are an excellent opportunity to demonstrate the power of the multi-omic approach coupled to AI with the goal of building predictive models for identifying and treating patients at higher risk," Helomics CTO Mark Collins said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.